Clinical Implications of Measuring Infliximab Levels and Human Anti-Chimeric Antibodies in Patients with Inflammatory Bowel Disease

被引：1
|
作者：
Rai, Tarun [1 ]
Navaneethan, Udayakumar [1 ]
Dalal, Deepan [1 ]
Lashner, Bret [1 ]
Shen, Bo [1 ]
机构：
[1] Cleveland Clin Fdn, Cleveland, OH 44195 USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2012年 / 107卷
关键词：
D O I：
10.14309/00000434-201210001-01572
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1572
引用
收藏
页码：S634 / S634
页数：1
相关论文
共 50 条
  • [1] Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Levels in Patients with Inflammatory Bowel Disease
    Afif, Waqqas
    Loftus, Edward V.
    Faubion, William A.
    Hanson, Karen A.
    Sandborn, William J.
    GASTROENTEROLOGY, 2009, 136 (05) : A147 - A147
  • [2] Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
    Afif, Waqqas
    Loftus, Edward V., Jr.
    Faubion, William A.
    Kane, Sunanda V.
    Bruining, David H.
    Hanson, Karen A.
    Sandborn, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (05): : 1133 - 1139
  • [3] Clinical Value of Measuring Trough Levels and Human Anti-Chimeric Antibodies in Patients With Inflammatory Bowel Disease Who Lost Response to Infliximab Therapy
    Pariente, Benjamin
    de Chambrun, Guillaume Pineton
    Desroches, Marine
    De Cassan, Chiara
    Gomet, Jean-Marc
    Desreumaux, Pierre
    Krzysiek, Roman
    Emilie, Dominique
    Colombel, Jean-Frederic
    Allez, Matthieu
    GASTROENTEROLOGY, 2011, 140 (05) : S277 - S277
  • [4] The Use of Human Anti-Chimeric Antibody (HACA) and Infliximab Levels in the Management of Inflammatory Bowel Disease
    Armbruster, Steven
    Ally, Mazer
    Maydonovitch, Corinne
    Betteridge, John
    Veerappan, Ganesh
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S641 - S641
  • [5] Does Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease Impact Clinical Management? A Canadian Experience.
    Chauhan, Usha
    Dutta, Usha
    Armstrong, David
    Greenwald, Eric
    Marshall, John
    Tse, Frances
    Xenodemetropoulos, Ted
    Smita, Halder
    INFLAMMATORY BOWEL DISEASES, 2012, 18 : S82 - S83
  • [6] Analysis of Clinical and Serological Associations, and the Clinical Consequences of the Development of Human Anti-Chimeric Antibodies (HACAs), and Low Serum Infliximab (IFX) Levels in Inflammatory Bowel Disease (IBD)
    Karsan, Sundip S.
    Cohen, Erica R.
    Targan, Stephan R.
    Ippoliti, Andrew
    Shih, David Q.
    Vasiliauskas, Eric A.
    Dubinsky, Marla
    Berel, Dror
    McGovern, Dermot P.
    GASTROENTEROLOGY, 2012, 142 (05) : S264 - S264
  • [7] THE CLINICAL AND FINANCIAL IMPACT OF MEASURING INFLIXIMAB LEVELS AND ANTIBODIES TO INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS
    O'Reilly, S.
    Keegan, D.
    Byrne, K.
    Sheridan, J.
    Mulcahy, H. E.
    Doherty, G. A.
    Cullen, G.
    GUT, 2017, 66 : A2 - A3
  • [8] Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease
    Steenholdt, Casper
    Al-khalaf, Magid
    Brynskov, Jorn
    Bendtzen, Klaus
    Thomsen, Ole O.
    Ainsworth, Mark A.
    INFLAMMATORY BOWEL DISEASES, 2012, 18 (12) : 2209 - 2217
  • [9] Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
    Choi, So Yoon
    Kang, Ben
    Lee, Jee Hyun
    Choe, Yon Ho
    GUT AND LIVER, 2017, 11 (01) : 55 - 61
  • [10] Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease
    Merras-Salmio, Laura
    Kolho, Kaija-Leena
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2017, 64 (02): : 272 - 278
12345